An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock

J Crit Care. 2022 Apr:68:144-154. doi: 10.1016/j.jcrc.2021.11.016. Epub 2021 Dec 9.

Abstract

Background: Our survey aimed to evaluate adherence to Surviving Sepsis Campaign (SSC) Guidelines 2016 among intensive care practitioners and to identify issues that remain controversial or lack clarity.

Methods: Members of the European Society of Intensive Care Medicine (ESICM) were surveyed using an anonymous web-based survey written by an international group of experts. The primary outcome measure was the rate of adherence to specific recommendations. Secondary outcomes were to describe areas of controversy and lack of data and to associate specific practices with clinician characteristics.

Results: Overall 820 questionnaires were completed. The SCC recommendations 2016 most adhered to were the choice of norepinephrine as first-line vasoactive drug (96.5%), vasopressor prescription based on therapeutic goal rather than dose (83.4%), targeting a specific mean arterial blood pressure during vasopressor use (77.9%), monitoring of blood pressure invasively (62.8%) and adding vasopressin or epinephrine as a second vasoactive agent (83.4%). We identified an internal conflict with regards to parallel versus sequential administration of fluids and vasoactive drugs and regional differences in practice that may be related to drug availabilities.

Conclusion: The use of vasopressors and fluid use in septic shock is largely compliant with current guidelines but several controversies should be addressed in future guideline iterations.

Keywords: Compliance; Dopamine (MeSH); Guidelines; Norepinephrine (MeSH); Sepsis (MeSH); Vasopressor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fluid Therapy
  • Humans
  • Resuscitation
  • Sepsis* / drug therapy
  • Shock, Septic* / drug therapy
  • Surveys and Questionnaires
  • Vasoconstrictor Agents / therapeutic use

Substances

  • Vasoconstrictor Agents